Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
La Revue De Medecine Interne|February 1, 1993
[Thrombotic thrombocytopenic purpura and ankylosing spondylarthritis. Apropos of a case]B Pallot-Prades, V Benvenuto, G Riffat, et al.
Revue Du Rhumatisme (Ed. Francaise : 1993)|December 1, 1994
[Functional ability and quality of life in rheumatoid arthritis: use of the Functional Independence Measure and the Reintegration to Normal Living Index]P Calmels, A Pereira, M Domenach, et al.
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires|November 30, 1991
[Bone histomorphometric study in involuted fractured osteoporosis treated with 1-ethane-1-hydroxybiphosphonate (etidronate) during one year]B Pallot-Prades, D Chappard, P Tavan, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 1, 1992
Contributions of chronological age, age at menarche and menopause and of anthropometric parameters to axial and peripheral bone densitiesL Vico, B Prallet, D Chappard, et al.
Annales D'Oto-Laryngologie Et De Chirurgie Cervico Faciale : Bulletin De La Societe D'Oto-Laryngologie Des Hopitaux De Paris|January 1, 1991
[Diagnostic and surgical strategy in sporadic primary hyperparathyroidism]J M Prades, B Pallot-Prades, B Estour, et al.
Annals of the Rheumatic Diseases|August 13, 2005
The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis populationH Marotte, B Pallot-Prades, L Grange, et al.
Annals of the Rheumatic Diseases|July 31, 2008
Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritisC Trocmé, H Marotte, A Baillet, et al.
Arthritis and Rheumatism|July 1, 2009
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registryF Tubach, D Salmon, P Ravaud, et al.
RMD Open|October 29, 2015
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registryJ H Salmon, P Cacoub, B Combe, et al.
Pageof 1